Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$535.0 million","upfrontCash":"$60.0 million","newsHeadline":"D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by D. E. Shaw Research

    Menu

    D. E. Shaw Research

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              D. E. Shaw Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly

              Details:

              DES-7114, is an orally administered, highly selective small-molecule inhibitor of the ion channel protein Kv1.3. It has recently completed Phase 1 clinical trials in healthy volunteers and has demonstrated efficacy in preclinical models of inflammatory and autoimmune diseases.

              Lead Product(s): DES-7114

              Therapeutic Area: Gastroenterology Product Name: DES-7114

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $535.0 million Upfront Cash: $60.0 million

              Deal Type: Licensing Agreement June 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY